Skip to main content

Table 2 Viremia of immunized goats following BVDV challenge using RT-qPCR

From: Recombinant E2 protein enhances protective efficacy of inactivated bovine viral diarrhea virus 2 vaccine in a goat model

Goat No.

aDays post-challenge

 

1

3

5

7

8

9

10

11

12

13

14

15

17

19

21

iBVDV+rE2

 241

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 250

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 546

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

rE2

 541

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 542

–

–

–

+

–

+

–

+

+

+b

–

–

–

+

–

 543

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

iBVDV

 37

–

–

–

+

–

–

–

–

–

–

–

–

–

–

–

 244

–

–

–

–

–

–

–

–

–

+

–

–

–

–

–

 246

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

Saline

 538

–

–

–

–

+

+

+

+

+

+

–

–

–

–

–

 539

–

–

–

+

+

+

+

+

+

+

–

–

–

–

–

 533

–

–

–

+

+

+

+

+

+

+

–

–

–

–

–

  1. aGoats were immunized twice intramuscularly with four different vaccine formulations: 1) inactivated BVDV+rE2, 2) rE2, 3) inactivated BVDV, and 4) saline, and challenged with 1 × 108 FAID50 BVDV/TW 2014 4 weeks after primary immunization. Viremia was detected using RT-qPCR for 21 days after challenge for each animal. Samples that reacted with the RT-qPCR were designated positive (+) and non-reactive samples were designated negative (−)
  2. bUsing the Pearson chi-square test, for viremia between 7 and 13 days post challenge, the p value was 0.017 when comparing between iBVDV+rE2 and rE2, and 0.147 when comparing between iBVDV+rE2 and iBVDV